{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-033574","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.081067+00:00","generated_at":"2026-06-27T09:16:14.324566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AlloVir reports FY2021 net loss $172M; cash $248.1M; three Phase 3 trials advancing","bullets":["Net loss $172.0M ($2.74/share) for 2021 vs. $69.8M in 2020; cash $248.1M at year-end.","Three Phase 3 registrational studies of posoleucel: HC, AdV treatment enrolling; multi-virus prevention expected 1H22.","R&D expenses $120.7M in 2021; 2022 operating expense guidance $130-145M (excl. stock comp).","ALVR106 Phase 1/2 for respiratory viruses initiated Dec 2021; ALVR107 preclinical for hepatitis B ongoing.","Initial data from posoleucel BK viremia POC study in kidney transplant expected 1H22."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-033574","json":"https://secwatch.observer/filing/0001193125-22-033574.json","markdown":"https://secwatch.observer/filing/0001193125-22-033574.md","text":"https://secwatch.observer/filing/0001193125-22-033574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522033574/0001193125-22-033574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522033574/d196801d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:16:14.324566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}